Fig. 3: EZH2 decreases TET1 expression via enhancement of H3K27me3 methylation in the promoter region of TET1.
From: SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1
A H3K27me3 level in GIST tissues and adjacent normal tissues measured by immunohistochemistry, scale bar: 50 μm. B qPCR results of the TET1 promoter region (EZH2 antibody) analyzed by ChIP (left) and the agarose gel electrophoresis detection results (right). C qPCR results of the TET1 promoter region (H3K27me3 antibody) analyzed by ChIP (left) and the agarose gel electrophoresis detection results (right). D Western blot analysis of TET1 and p53 proteins in sh-EZH2-treated GIST-T1 cells. *p < 0.05 vs. adjacent normal tissues, sh-NC-treated GIST-T1 cells or GIST-T1 cells incubated with sh-NC + IgG. #p < 0.05 vs. GIST-T1 cells incubated with sh-EZH2 + IgG. Measurement data were expressed as mean ± standard deviation. Unpaired t-test was used for two-group data comparison. The cell experiment was repeated three times.
